文摘
摘要目的:评估τPET-to-autopsy相关性在横断面样本不同的神经退行性疾病的患者。
背景:的相关性[18 f] Flortaucipir宠物(FTP)尸检病理诊断和事后τ是有限的。
设计/方法:15个患者,经FTP接受尸检(平均年龄60岁,标准差[停工]14;南达科他州拉平均PET-to-autopsy时间27个月15)。神经成像:病人FTP 80 - 100分钟标准摄入值比率(SUVR)图像(小脑灰质引用)是在88年SUVR amyloid-negative相比,认知正常的控件(CN;平均年龄66年金丝20)。SUVRs相应地区14 Braak阶段比较年轻,non-autopsy控件(YC;平均年龄26岁。4.6)用作tau-negative标准。神经病理学:蒙蔽尸检是使用一个研究协议完成。
结果:主要解剖诊断包括阿尔茨海默氏症(广告;n = 4),进行性核上的麻痹(PSP;n = 4), corticobasal变性(CBD;n = 2), FTLD-tauMAPT突变(n = 2), argyrophilic谷物疾病(AGD短;n = 1), TDP-43 B型(n = 1),和FTLD-FUS (n = 1)。患者主要广告病理有强烈的皮质示踪剂保留,特别是在顶叶,对应的τ神经原纤维缠结(非功能性测试)病理。CBD患者不同示踪剂保留在额叶白质和纹状体与τ病理相关。其他tauopathies (PSP, AGD FTLD-tau)和FTLD-TDP /付显示轻度升高FTP绑定与中枢神经系统相比,通常在地区严重的退化。患者主要广告病理学(Braak VI)升高SUVRs所有地区比其他病人和yc (p < 0.001,每个地区)。患者Braak I-IV非功能性测试co-pathology没有显示高架SUVRs YC相比(下面的意思是加两道。阈值计算YC SUVRs在每个地区)。
结论:FTP杰出的广告和non-AD主要病理。CBD可以区别于其他疾病。其他non-AD tauopathies和FTLD-TDP /付显示低水平难以区分的示踪绑定控件。FTP没有检测Braak I-IV非功能性测试病理学。
披露:Soleimani-Meigooni博士没有披露。Iaccarino博士没有披露。拉博士生活乐趣没有披露。贝克博士没有披露。Bourakova博士没有披露。拳击手博士已经收到个人赔偿咨询、担任科学顾问委员会说,与AbbVie或其他活动,Asceneuron, Cellgene, Ipierian, Ionis,詹森,默克公司、诺华、富山和联合银行。拳击手博士持有股票或股票期权在Alector和Aeton疗法。拳击手博士收到NIH的研究支持,τ财团,加州大学治疗阿尔茨海默病的计划,Bluefield项目治愈FTD, Corticobasal变性解决方案,和以下公司:热心,生原体,百时美施贵宝公司,C2N诊断,Cortice Bios。爱德华兹博士没有披露。es博士没有披露。 Dr. Gorno Tempini has nothing to disclose. Dr. Jagust has nothing to disclose. Dr. Janabi has nothing to disclose. Dr. Kramer has nothing to disclose. Dr. Lesman-Segev has nothing to disclose. Dr. Mellinger has nothing to disclose. Dr. Miller has nothing to disclose. Dr. Pham has nothing to disclose. Dr. Rosen has nothing to disclose. Dr. Spina has nothing to disclose. Dr. Strom has nothing to disclose. Dr. Seeley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bristol Myers-Squibb, Merck Inc., and Biogen. Dr. Grinberg has nothing to disclose. Dr. Rabinovici has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Axon Neurosicience, and GE Healthcare. Dr. Rabinovici has received personal compensation in an editorial capacity for JAMA Neurology. Dr. Rabinovici has received research support from Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare, Piramal, and Life Molecular Imaging.
